A Phase II, Open-Label, Multicenter, Multicohort Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Patients With Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Atezolizumab (Primary) ; Cobimetinib (Primary)
- Indications Head and neck cancer; Renal cell carcinoma; Solid tumours; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Roche
- 07 Nov 2017 Status changed from not yet recruiting to recruiting.
- 26 Sep 2017 Planned initiation date changed from 21 Sep 2017 to 21 Oct 2017.
- 02 Sep 2017 New trial record